Assets Acquisition

12 Months Ended

Jun. 30, 2026

Assets Acquisition [Abstract]

ASSETS ACQUISITION

NOTE 22 — ASSETS ACQUISITION

Hupan Pharmaceutical (Hubei) Co., Ltd acquisition

On November 5, 2024, the Company entered into an equity transfer agreement (the “Equity Transfer Agreement”) with Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd to acquire 100% of the equity interests in Hupan Pharmaceutical (Hubei) Co., Ltd (“Hupan Pharmaceutical”), a pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China.

Pursuant to the Equity Transfer Agreement, Sichuan Hupan will acquire the entirety of the equity interests that Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd. hold in Hupan Pharmaceutical, for a total consideration of RMB4.0 million (US$552,730).

The acquisition was accounted for as an asset acquisition because the acquisition was related to the pharmaceutical distribution license, a single asset. The acquisition was closed on November 21, 2024. The following table summarizes the fair value of the identifiable assets:

		Amount

Total consideration in cash		$	552,730

Assets acquired and liabilities assumed:
Cash acquired			9
Original paid in capital paid to Hupan Pharmaceutical			276,365
Intangible assets – license of pharmaceutical distribution			418,867
Other payables			(37,794	)
Deferred tax liabilities			(104,717	)
Total assets acquired		$	552,730

The Company recorded impairment of intangible assets of nil for the years ended June 30, 2026 and 2025.